Technical Analysis for CYTR - CytRx Corporation

Grade Last Price % Change Price Change
grade C 0.61 3.39% 0.02
CYTR closed up 3.39 percent on Wednesday, January 16, 2019, on 1.35 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CYTR trend table...

Date Alert Name Type % Chg
Jan 16 Pocket Pivot Bullish Swing Setup 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 16 Overbought Stochastic Strength 0.00%
Jan 15 Crossed Above 50 DMA Bullish 3.39%
Jan 15 Boomer Buy Setup Bullish Swing Setup 3.39%
Jan 15 NR7 Range Contraction 3.39%
Jan 15 NR7-2 Range Contraction 3.39%
Jan 15 Wide Bands Range Expansion 3.39%
Jan 15 Overbought Stochastic Strength 3.39%
Jan 14 Fell Below 50 DMA Bearish 6.09%

Older signals for CYTR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. The company also has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas; completed its Phase 1b/2 clinical trial primarily in the same indication; and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. In addition, the company is evaluating a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Is CYTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.35
52 Week Low 0.33
Average Volume 172,490
200-Day Moving Average 1.0747
50-Day Moving Average 0.5709
20-Day Moving Average 0.4959
10-Day Moving Average 0.5672
Average True Range 0.0482
ADX 38.03
+DI 22.285
-DI 12.7767
Chandelier Exit (Long, 3 ATRs ) 0.4904
Chandelier Exit (Short, 3 ATRs ) 0.4746
Upper Bollinger Band 0.6546
Lower Bollinger Band 0.3372
Percent B (%b) 0.86
BandWidth 64.00484
MACD Line 0.0126
MACD Signal Line -0.0086
MACD Histogram 0.0212
Fundamentals Value
Market Cap 101.09 Million
Num Shares 166 Million
EPS -0.41
Price-to-Earnings (P/E) Ratio -1.50
Price-to-Sales 593.24
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.68
Resistance 3 (R3) 0.68 0.66 0.67
Resistance 2 (R2) 0.66 0.64 0.66 0.66
Resistance 1 (R1) 0.63 0.63 0.65 0.63 0.66
Pivot Point 0.61 0.61 0.62 0.61 0.61
Support 1 (S1) 0.59 0.59 0.60 0.59 0.56
Support 2 (S2) 0.57 0.58 0.57 0.56
Support 3 (S3) 0.54 0.57 0.55
Support 4 (S4) 0.54